Effect of 0.025% FK-506 eyedrops on botulinum toxin B–induced mouse dry eye

Bin Wu Lin, Mei Zhu Chen, Shu Xian Fan, Roy S. Chuck, Shi You Zhou

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PURPOSES. To investigate the effect of FK-506 eye drops on Botulinum toxin B (BTX-B)-induced mouse dry eye.

METHODS. Forty-five CBA/J mice were followed up for 4 weeks after treatment with 0.025% FK-506, vehicle or 0.9% saline eye drops 3 days after intralacrimal glands injection with 20 milliunits BTX-B. Tear production, corneal fluorescein staining, the mRNA, and protein expression of cytokines were measured. The activation of nuclear factor–κB (NF-κB) was detected by Western blotting. The infiltration of inflammatory cells was examined by immunohistochemistry.

RESULTS. After treated with FK-506 eye drops, aqueous tear production in the mice began to recover at week 1, and then increased to the levels of pre–BTX-B injection at week 4 (2.21 ± 0.43 vs. 2.52 ± 0.71 mm, t = 0.84, P > 0.05). The severity of corneal epithelial defects was alleviated at week 2 and further improved at week 4 when compared with those in the vehicle- and saline-treated groups. The gene expression of IL-1β and TNF-α in the FK-506 and vehicle-treated groups were 47.01% and 45.56%, 85.91% and 115.83% of that in the salinetreated group in the ocular surface, while in the lacrimal glands 49.16% and 67.60%, 94.91% and 95.77% of that in the saline-treated group, respectively. The ratio of phosphorylated IκB-α to total IκB-α in the keratoconjunctival tissues was lower in the FK-506–treated group than in the vehicle- and saline-treated groups (both P < 0.05). No inflammatory cells were detected in all groups.

CONCLUSIONS. Topical application of FK-506 can inhibit NF-κB activation and related inflammatory response and alleviate the signs of dry eye.

Original languageEnglish (US)
Pages (from-to)45-53
Number of pages9
JournalInvestigative Ophthalmology and Visual Science
Volume56
Issue number1
DOIs
StatePublished - Nov 19 2014

Fingerprint

Botulinum Toxins
Ophthalmic Solutions
Tacrolimus
Tears
Lacrimal Apparatus
Inbred CBA Mouse
Injections
Fluorescein
Interleukin-1
Western Blotting
Immunohistochemistry
Staining and Labeling
Cytokines
Gene Expression
Messenger RNA
Proteins

Keywords

  • Dry eye
  • FK-506
  • Inflammation
  • NF-κB

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Effect of 0.025% FK-506 eyedrops on botulinum toxin B–induced mouse dry eye. / Lin, Bin Wu; Chen, Mei Zhu; Fan, Shu Xian; Chuck, Roy S.; Zhou, Shi You.

In: Investigative Ophthalmology and Visual Science, Vol. 56, No. 1, 19.11.2014, p. 45-53.

Research output: Contribution to journalArticle

Lin, Bin Wu ; Chen, Mei Zhu ; Fan, Shu Xian ; Chuck, Roy S. ; Zhou, Shi You. / Effect of 0.025% FK-506 eyedrops on botulinum toxin B–induced mouse dry eye. In: Investigative Ophthalmology and Visual Science. 2014 ; Vol. 56, No. 1. pp. 45-53.
@article{5b99b596560443a897f3c55e5812e618,
title = "Effect of 0.025{\%} FK-506 eyedrops on botulinum toxin B–induced mouse dry eye",
abstract = "PURPOSES. To investigate the effect of FK-506 eye drops on Botulinum toxin B (BTX-B)-induced mouse dry eye.METHODS. Forty-five CBA/J mice were followed up for 4 weeks after treatment with 0.025{\%} FK-506, vehicle or 0.9{\%} saline eye drops 3 days after intralacrimal glands injection with 20 milliunits BTX-B. Tear production, corneal fluorescein staining, the mRNA, and protein expression of cytokines were measured. The activation of nuclear factor–κB (NF-κB) was detected by Western blotting. The infiltration of inflammatory cells was examined by immunohistochemistry.RESULTS. After treated with FK-506 eye drops, aqueous tear production in the mice began to recover at week 1, and then increased to the levels of pre–BTX-B injection at week 4 (2.21 ± 0.43 vs. 2.52 ± 0.71 mm, t = 0.84, P > 0.05). The severity of corneal epithelial defects was alleviated at week 2 and further improved at week 4 when compared with those in the vehicle- and saline-treated groups. The gene expression of IL-1β and TNF-α in the FK-506 and vehicle-treated groups were 47.01{\%} and 45.56{\%}, 85.91{\%} and 115.83{\%} of that in the salinetreated group in the ocular surface, while in the lacrimal glands 49.16{\%} and 67.60{\%}, 94.91{\%} and 95.77{\%} of that in the saline-treated group, respectively. The ratio of phosphorylated IκB-α to total IκB-α in the keratoconjunctival tissues was lower in the FK-506–treated group than in the vehicle- and saline-treated groups (both P < 0.05). No inflammatory cells were detected in all groups.CONCLUSIONS. Topical application of FK-506 can inhibit NF-κB activation and related inflammatory response and alleviate the signs of dry eye.",
keywords = "Dry eye, FK-506, Inflammation, NF-κB",
author = "Lin, {Bin Wu} and Chen, {Mei Zhu} and Fan, {Shu Xian} and Chuck, {Roy S.} and Zhou, {Shi You}",
year = "2014",
month = "11",
day = "19",
doi = "10.1167/iovs.13-12925",
language = "English (US)",
volume = "56",
pages = "45--53",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of 0.025% FK-506 eyedrops on botulinum toxin B–induced mouse dry eye

AU - Lin, Bin Wu

AU - Chen, Mei Zhu

AU - Fan, Shu Xian

AU - Chuck, Roy S.

AU - Zhou, Shi You

PY - 2014/11/19

Y1 - 2014/11/19

N2 - PURPOSES. To investigate the effect of FK-506 eye drops on Botulinum toxin B (BTX-B)-induced mouse dry eye.METHODS. Forty-five CBA/J mice were followed up for 4 weeks after treatment with 0.025% FK-506, vehicle or 0.9% saline eye drops 3 days after intralacrimal glands injection with 20 milliunits BTX-B. Tear production, corneal fluorescein staining, the mRNA, and protein expression of cytokines were measured. The activation of nuclear factor–κB (NF-κB) was detected by Western blotting. The infiltration of inflammatory cells was examined by immunohistochemistry.RESULTS. After treated with FK-506 eye drops, aqueous tear production in the mice began to recover at week 1, and then increased to the levels of pre–BTX-B injection at week 4 (2.21 ± 0.43 vs. 2.52 ± 0.71 mm, t = 0.84, P > 0.05). The severity of corneal epithelial defects was alleviated at week 2 and further improved at week 4 when compared with those in the vehicle- and saline-treated groups. The gene expression of IL-1β and TNF-α in the FK-506 and vehicle-treated groups were 47.01% and 45.56%, 85.91% and 115.83% of that in the salinetreated group in the ocular surface, while in the lacrimal glands 49.16% and 67.60%, 94.91% and 95.77% of that in the saline-treated group, respectively. The ratio of phosphorylated IκB-α to total IκB-α in the keratoconjunctival tissues was lower in the FK-506–treated group than in the vehicle- and saline-treated groups (both P < 0.05). No inflammatory cells were detected in all groups.CONCLUSIONS. Topical application of FK-506 can inhibit NF-κB activation and related inflammatory response and alleviate the signs of dry eye.

AB - PURPOSES. To investigate the effect of FK-506 eye drops on Botulinum toxin B (BTX-B)-induced mouse dry eye.METHODS. Forty-five CBA/J mice were followed up for 4 weeks after treatment with 0.025% FK-506, vehicle or 0.9% saline eye drops 3 days after intralacrimal glands injection with 20 milliunits BTX-B. Tear production, corneal fluorescein staining, the mRNA, and protein expression of cytokines were measured. The activation of nuclear factor–κB (NF-κB) was detected by Western blotting. The infiltration of inflammatory cells was examined by immunohistochemistry.RESULTS. After treated with FK-506 eye drops, aqueous tear production in the mice began to recover at week 1, and then increased to the levels of pre–BTX-B injection at week 4 (2.21 ± 0.43 vs. 2.52 ± 0.71 mm, t = 0.84, P > 0.05). The severity of corneal epithelial defects was alleviated at week 2 and further improved at week 4 when compared with those in the vehicle- and saline-treated groups. The gene expression of IL-1β and TNF-α in the FK-506 and vehicle-treated groups were 47.01% and 45.56%, 85.91% and 115.83% of that in the salinetreated group in the ocular surface, while in the lacrimal glands 49.16% and 67.60%, 94.91% and 95.77% of that in the saline-treated group, respectively. The ratio of phosphorylated IκB-α to total IκB-α in the keratoconjunctival tissues was lower in the FK-506–treated group than in the vehicle- and saline-treated groups (both P < 0.05). No inflammatory cells were detected in all groups.CONCLUSIONS. Topical application of FK-506 can inhibit NF-κB activation and related inflammatory response and alleviate the signs of dry eye.

KW - Dry eye

KW - FK-506

KW - Inflammation

KW - NF-κB

UR - http://www.scopus.com/inward/record.url?scp=84920548970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920548970&partnerID=8YFLogxK

U2 - 10.1167/iovs.13-12925

DO - 10.1167/iovs.13-12925

M3 - Article

C2 - 25491293

AN - SCOPUS:84920548970

VL - 56

SP - 45

EP - 53

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 1

ER -